Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P63167
UPID:
DYL1_HUMAN
Alternative names:
8 kDa dynein light chain; Dynein light chain LC8-type 1; Protein inhibitor of neuronal nitric oxide synthase
Alternative UPACC:
P63167; Q15701
Background:
Dynein light chain 1, cytoplasmic, also known as an 8 kDa dynein light chain or Dynein light chain LC8-type 1, plays a crucial role in the intracellular retrograde motility of vesicles and organelles along microtubules. It serves as a non-catalytic accessory component of the cytoplasmic dynein 1 complex, linking dynein to cargos and adapter proteins that regulate its function. Additionally, it binds and inhibits neuronal nitric oxide synthase, influences the transactivation functions of ESR1, and regulates apoptotic activities by interacting with BCL2L11.
Therapeutic significance:
Understanding the role of Dynein light chain 1, cytoplasmic could open doors to potential therapeutic strategies.